Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias-Reference-Cited by-同舟云学术

Cytotoxic T-lymphocytes recognizing P-glycoprotein in murine multidrug-resistant leukemias

Published:2009-04-24 Issue:1 Volume:59 Page:14-19
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

Azuma Eiichi,Masuda Shinichi,Qi Jiang,Kumamoto Tadashi,Hirayama Masahiro,Nagai Masataka,Hiratake Shinya,Umemoto Masakazu,Komada Yoshihiro,Sakurai Minoru

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.1997.tb00954.x/fullpdf

Reference27 articles.

1. Multidrug resistance in cancer;Kartner;Sci Am,1989

2. Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein;Foxwell;Mol Pharmacol,1989

3. Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligodeoxynucleotide does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line;Rivoltini;Int J Cancer,1990

4. Immunosuppressants FK506 and rapamycin function as reversal agents of the multidrug resistance phenotype;Arceci;Blood,1992

5. Mouse-human chimeric antibody MH171 against the multidrug transporter P-glycoprotein;Ariyoshi;Jpn J Cancer Res,1992

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro;Journal of Experimental & Clinical Cancer Research;2010-08-30

2. The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTXin Vitroandin Vivo;Cancer Biotherapy and Radiopharmaceuticals;2009-02

3. Acquisition of multidrug resistance by L1210 leukemia cells decreases their tumorigenicity and enhances their susceptibility to the host immune response;Cancer Immunology, Immunotherapy;2004-12-04

4. Multidrug resistance‐1 (MDR‐1): a new target for T cell‐based immunotherapy;The FASEB Journal;2004-10-21